AcuCort AB (ACUC.ST)
SEK 0.65
(-3.25%)
SEK 0.65
(-3.25%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.16 SEK | 57.89% |
| 2022 | -0.38 SEK | -31.03% |
| 2021 | -0.29 SEK | 3.33% |
| 2020 | -0.30 SEK | 6.25% |
| 2019 | -0.32 SEK | 25.58% |
| 2018 | -0.43 SEK | -2.38% |
| 2017 | -0.42 SEK | -140.0% |
| 2016 | -0.18 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.04 SEK | 16.34% |
| 2024 Q2 | -0.03 SEK | 25.81% |
| 2023 Q4 | -0.05 SEK | 35.51% |
| 2023 Q3 | -0.08 SEK | -11.0% |
| 2023 FY | - SEK | 57.89% |
| 2023 Q2 | -0.07 SEK | 17.75% |
| 2023 Q1 | -0.09 SEK | 10.46% |
| 2022 Q1 | -0.09 SEK | -20.21% |
| 2022 FY | - SEK | -31.03% |
| 2022 Q3 | -0.10 SEK | -9.83% |
| 2022 Q2 | -0.09 SEK | 5.25% |
| 2022 Q4 | -0.10 SEK | -0.31% |
| 2021 Q3 | -0.11 SEK | 0.0% |
| 2021 FY | - SEK | 3.33% |
| 2021 Q4 | -0.08 SEK | 29.36% |
| 2020 FY | - SEK | 6.25% |
| 2019 FY | - SEK | 25.58% |
| 2018 FY | - SEK | -2.38% |
| 2017 FY | - SEK | -140.0% |
| 2016 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AlzeCure Pharma AB (publ) | -0.60 SEK | 73.333% |
| BioGaia AB (publ) | 3.62 SEK | 104.42% |
| Enzymatica AB (publ) | -0.28 SEK | 42.857% |
| Enorama Pharma AB (publ) | -1.61 SEK | 90.062% |
| Gabather AB (publ) | -0.65 SEK | 75.385% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | 55.556% |
| Moberg Pharma AB (publ) | -1.33 SEK | 87.97% |
| Nanexa AB (publ) | -1.09 SEK | 85.321% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 77.778% |
| ODI Pharma AB | 0.02 SEK | 783.761% |
| Orexo AB (publ) | -3.73 SEK | 95.71% |
| Probi AB (publ) | 1.48 SEK | 110.811% |
| Swedencare AB (publ) | 0.37 SEK | 143.243% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 102.142% |
| Toleranzia AB | -0.06 SEK | -185.714% |
| Vivesto AB | -0.74 SEK | 78.378% |